Cost For Biologics A Hurdle Too High In China? Think Again
This article was originally published in Scrip
Even in China where patients pay out-of-pocket for high-priced innovative treatments such as cancer therapies and biologics, drug costs are not the only factor influencing patients and doctors, notes a new study by Johnson & Johnson.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.